Daiichi Sankyo Co Ltd

Type: Company
Name: Daiichi Sankyo Co Ltd (Daiichi Sankyo Company Limited)
First reported 20 hours ago - Updated 20 hours ago - 1 reports
GlaxoSmithKline plc
GlaxoSmithKline plc

GlaxoSmithKline, Ranbaxy among hardest hit in Indian price cuts

Officials second-guess foreign investment as cost crackdown continuesShareToolsIndia's skeptical patent regime is only one of pharma's worries in the country. New price controls are on their way, and brokerage house HSBC has identified which companies ... [Published FiercePharma - 20 hours ago]
First reported May 19 2013 - Updated May 19 2013 - 1 reports

India invites investment from Japan in electronics

Keywords:Japan electronic hardware investment India Investment RoundtableIndia has invited Japan to invest in sectors like infrastructure and electronic hardware to strengthen trade relations between the countries.Commerce, Industry and Textiles Minister ... [Published EE Times India - May 19 2013]
First reported May 19 2013 - Updated May 19 2013 - 1 reports
Ranbaxy Laboratories Ltd
Ranbaxy Laboratories Ltd

Why did drug firm ignore warnings?

It’s a sad commentary on the integrity of a company like Ranbaxy, one of India’s top pharmaceutical firms, that its American arm was compelled to plead guilty to distributing adulterated drugs made in India in the United States in 2005-06.What is inexplicable ... [Published Deccan Chronicle - May 19 2013]
First reported May 17 2013 - Updated May 18 2013 - 3 reports
Anand Sharma
Anand Sharma

Invest more in core sector, Sharma to Japan

The government has urged for Japanese investment into sectors such as infrastructure and electronic hardware in a bid to better bilateral ties between both the country.The Union Minister of Commerce, Industry and Textiles Anand Sharma asked Japanese industrialists, ... [Published New Indian Express - May 18 2013]
Entities: Anand Sharma, Japan, India
First reported May 16 2013 - Updated May 16 2013 - 2 reports
Daiichi Sankyo Co Ltd
Daiichi Sankyo Co Ltd

Daiichi Sankyo’s Japan Sales Up 8% After Long-Term Prescription Bans Lifted

Daiichi Sankyo’s 2012 Japan sales were ¥442.5 billion, thanks to prescription limits were lifted for Alzheimer drug Memary (memantine) and PPI Nexium (esomeprazole). ... [Published The Rose Sheet - May 16 2013]
First reported May 15 2013 - Updated May 16 2013 - 2 reports
Manufacturing
Manufacturing

Why did drug firm ignore warnings?

It was suicidal on Ranbaxy’s part to have indulged in such gross violation of good manufacturing practices when there was so much at stakeIt was suicidal on Ranbaxy’s part to have indulged in such gross violation of good manufacturing practices when ... [Published Asian Age - May 15 2013]
First reported May 15 2013 - Updated May 15 2013 - 1 reports
Eisai Co Ltd
Eisai Co Ltd

Japanese Pharmaceutical Industry Reviewed by GBI Research in In-Demand Study Now Available at MarketPublishers.com

By a News Reporter-Staff News Editor at China Weekly News Japan's pharmaceutical industry, the world's second largest, was worth USD 89 billion in 2011, representing 10 per cent of the global market share. However, the industry growth has been hindered ... [Published Pharmacy Choice - May 15 2013]
First reported May 15 2013 - Updated May 15 2013 - 1 reports

Daiichi Sankyo's net jumps to ¥66.6 bn in FY'13, annual dividend at ¥60 per share

Daiichi Sankyo's net jumps to ¥66.6 bn in FY'13, annual dividend at ¥60 per shareOur Bureau, MumbaiDaiichi Sankyo Company, Japan, has posted strong growth in bottom line during the year ended March 2013 to ¥66.6 billion from ¥10.4 billion in the previous ... [Published PharmaBiz - May 15 2013]
First reported May 15 2013 - Updated May 15 2013 - 2 reports

Daiichi Sankyo To Send More Personnel To Improve Ranbaxy Quality

Home » Blogs » Related Biotechnology, Pharmaceutical and Healthcare NewsDaiichi Sankyo plans to pour more of its personnel into India to help beef up quality control at its Ranbaxy Laboratories unit and get two of its plants back exporting generic drugs ... [Published BioPortfolio - May 15 2013]
First reported May 14 2013 - Updated May 14 2013 - 1 reports

Six Years Later, Ranbaxy - Oops, Daiichi Sankyo - Pleads Guilty to Adulteration, Pays $500 Million

It only took until 2013, but the US Food and Drug Administration finally secured guilty pleas and fines.  The basics are in an Associated Press story ( via the Washington Post ): A subsidiary of India’s largest pharmaceutical company has agreed to pay ... [Published Health Care Renewal - May 14 2013]
First reported May 14 2013 - Updated May 14 2013 - 1 reports

What's an impairment?

Tata Steel Ltd said on Monday it will take a significant hit on its profit and loss account for the year ended 31 March because of a one-off write-down of $1.6 billion, largely related to its beleaguered European operations that have been buffeted by ... [Published Individual.com - May 14 2013]
First reported May 14 2013 - Updated May 14 2013 - 1 reports

Daiichi Sankyo's India unit to pay $500 million in settlement

MUMBAI, May 14 (Kyodo) - Ranbaxy Laboratories Ltd., an Indian subsidiary of Japan's Daiichi Sankyo Co., has agreed to pay $500 million to the U.S. Justice Department to settle felony charges related to drug safety, local media reported Tuesday.In the ... [Published Pharmacy Choice - May 14 2013]

Quotes

...U S -based Mylan ($MYL) is involved in two of those, while Japan-based Terumo filed another. One official told the ET that "the policy needs to be relooked at the highest level."
GlaxoSmithKline, Ranbaxy among hardest hit in Indian price cuts [Published FiercePharma - 20 hours ago]
"The successful joint ventures between India and Japan in the auto sector could be a role model for Indian and Japanese collaboration in other sectors including services" said Vikram Kirloskar, vice chairman, Toyota Kirloskar Motor Company
India invites investment from Japan in electronics [Published EE Times India - May 19 2013]
...updated the Japanese business community that India is now open for multi-brand retail and civil aviation investments by foreign players and "more reforms in insurance and pension sectors, among others, were in the pipeline"
India Urges Japan To Invest In Electronics ... [Published EFYTimes.com - May 17 2013]
Reporters obtained the following quote from the background information supplied by the inventors: "The present invention generally relates to diabetic conditions and drug products for treatment of these conditions."
Patent Application Titled "Co-Therapy for Diabetic Conditions" Published Online [Published NewsRX - May 17 2013]

More Content

All (360) | News (282) | Reports (6) | Blogs (29) | Audio/Video (0) | Fact Sheets (4) | Press Releases (39)
sort by: Date | Relevance
First ever exclusively corporate at IMEX sets h... [Published Travel News - 6 hours ago]
GlaxoSmithKline, Ranbaxy among hardest hit in I... [Published FiercePharma - 20 hours ago]
Pfizer Inc. (PFE), AstraZeneca plc (ADR) (AZN):... [Published InsiderMonkey.com - 23 hours ago]
Overseas Stocks - May 20 [Published Trading Room - May 19 2013]
India invites investment from Japan in electronics [Published EE Times India - May 19 2013]
Why did drug firm ignore warnings? [Published Deccan Chronicle - May 19 2013]
Statin Users May Have a Reason to Rejoice After... [Published EquityJungle - v0.1 - May 19 2013]
DIPP wants relook of FDI policy in pharma at PM... [Published Hindu Business Line - May 19 2013]
Invest more in core sector, Sharma to Japan [Published New Indian Express - May 18 2013]
India Urges Japan To Invest In Electronics ... [Published EFYTimes.com - May 17 2013]
Anand Sharma invites Japanese Inc to invest in ... [Published TruthDive - May 17 2013]
India invites investment from Japan in infra, e... [Published Economic Times - May 17 2013]
Patent Application Titled "Co-Therapy for Diabe... [Published NewsRX - May 17 2013]
Daiichi Sankyo’s Japan Sales Up 8% After Long-T... [Published The Rose Sheet - May 16 2013]
Daiichi Sankyo’s Japan Sales Up 8% After Long-T... [Published BioPortfolio - May 16 2013]
After swallowing bitter pill, Ranbaxy set to re... [Published Firstpost.com - May 16 2013]
Fraud at Ranbaxy: David's Sleazy Behavior [Published Hooked: Ethics, Medicine, and Pharma - May 16 2013]
Why did drug firm ignore warnings? [Published Asian Age - May 15 2013]
Japanese Pharmaceutical Industry Reviewed by GB... [Published Pharmacy Choice - May 15 2013]
Art Pappas Elected to NVCA Board of Directors P... [Published Yahoo! Finance - May 15 2013]
The epic inside story of fraud at a generic Lip... [Published Fortune - May 15 2013]
Ranbaxy Pays $500 Million Fine for Selling Bad ... [Published CorpWatch - May 15 2013]
Daiichi Sankyo's net jumps to ¥66.6 bn in FY'1... [Published PharmaBiz - May 15 2013]
From Tata to Ranbaxy: M&As in good times is lik... [Published Firstpost.com - May 15 2013]
Daiichi Sankyo To Send More Personnel To Improv... [Published BioPortfolio - May 15 2013]
Corus, Ranbaxy & the curse: Deals that happen i... [Published Economic Times - May 15 2013]
Ranbaxy to pop rebuild pill [Published Calcutta Telegraph - May 15 2013]
Daiichi Sankyo To Send More Personnel To Improv... [Published The Rose Sheet - May 15 2013]
Ranbaxy ‘systematically violated’ good manufact... [Published New Delhi Pioneer - May 14 2013]
Shares in Indian drug-maker climb as US legal b... [Published Qatar Peninsula - May 14 2013]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
Anand Sharma, Paolo Pucci, Jeanne Andrade, [more]
  •  
Ranbaxy Laboratories Ltd, ArQule Inc, Astellas Pharma Inc, [more]
  •  
FDA Food & Drug Administration, US Department of Justice, Bill & Melinda Gates Foundation, [more]
  •  
Drugs, Tivantinib, Dysuria, [more]
  •  
Edoxaban, Lipitor, Camptosar, [more]
  •  
Tokyo, Odawara (Japan), Nagoya, [more]
  •  
Japan, Brazil, India, [more]
  •  
Medicine, Biotechnology, Medication, [more]
  •  
Pharma & Biotech, Health, Telecom, [more]
Daiichi Pharmaceutical, BioPortfolio, PharmaBiz, [more]
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Statin Users May Have a Reason to Rejoice After... [Published EquityJungle - v0.1 - May 19 2013]
Filed under: Investing Whether or not you've been keeping tabs, the American Society of Clinical Oncology's annual meeting is less than two weeks away. ASCO, as it's more commonly known, is arguably the single-most important event in the biotechnology ...
Fraud at Ranbaxy: David's Sleazy Behavior [Published Hooked: Ethics, Medicine, and Pharma - May 16 2013]
I have not blooged much about the Indian generic drug company, Ranbaxy (one previous post: http://brodyhooked.blogspot.com/2011/12/time-out-for-some-drug-pricing-issues.html --was really mostly about Pfizer and how they planned to protect their profits ...
Six Years Later, Ranbaxy - Oops, Daiichi Sankyo... [Published Health Care Renewal - May 14 2013]
It only took until 2013, but the US Food and Drug Administration finally secured guilty pleas and fines.  The basics are in an Associated Press story ( via the Washington Post ): A subsidiary of India’s largest pharmaceutical company has agreed to pay ...
Perosphere, Daiichi Sankyo sign PER977 clinical... [Published PBR - News - Apr 26 2013]
Perosphere and Daiichi Sankyo have signed a clinical trial deal to evaluate the efficacy and safety of PER977 to reverse the anticoagulant activity of edoxaban. ...
Daiichi enrolls first patient in two pivotal ph... [Published PBR - News - Apr 25 2013]
Daiichi Sankyo Company has announced the enrollment of the first patient in two pivotal phase 3 trials of nimotuzumab (DE-766) that is being evaluated as lung cancer and gastric cancer therapeutic. ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Ranbaxy Announces Conclusion of Previously Disc... [Published Business Wire - May 13 2013]
Seattle Genetics Reports First Quarter 2013 Fin... [Published Business Wire - May 07 2013]
Japanese Pharmaceutical Industry Reviewed by GB... [Published Business Wire - May 07 2013]
Research and Markets: Japan Pharmaceutical Mark... [Published Business Wire - May 01 2013]
Perosphere and Daiichi Sankyo Enter into a Clin... [Published PR Newswire: Health - Apr 25 2013]
1 2 3 4 5 6 7 8
About
Silobreaker
Press Room
Products
Online Service
On-Premises Software
Contact Us
Sales
Support
Legal
Terms of Use
Privacy Policy


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2013 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.